The COVID-19 pandemic has dramatically challenged care for cancer patients, especially those with active treatment that represent a vulnerable population for SARS-CoV-2 infection. Aggressive lymphoid neoplasms, such as diffuse large B-cell lymphoma and high-grade B-cell lymphoma, need to be treated without delay in order to get the best disease outcome. Because of that, our clinical practice was changed so as to minimize risk of SARS-CoV-2 infection while continuing haematological treatment. In this report, we analyse the management of front-line therapy in 18 patients during COVID-19 outbreak, as well as the results of the implemented measures in their outcome.
Managing the front-line treatment for diffuse large B-cell lymphoma and high-grade B-cell lymphoma during the COVID-19 outbreak